Shots: HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded […]readmore
Tags : technology
Shots: Ligand to receive upfront, milestones, and royalties for each of the product developed using OmniAb technology. Genagon to get WW rights for Ligand’s Omniab technology including the developed products […]readmore
Shots: Celgene to utilize Obsidian’s DDs (Destabilizing Domains) technology for its cell therapy candidates with DD-regulated IL12 or CD40L proteins for oncology indications Obsidian will receive an undisclosed upfront in […]readmore
Shots: Biomunex to receive upfronts and milestones from Sanofi. Sanofi to get rights to access Biomunex’s BiXAb technology for the development of bi- and multi-specific antibody therapies and will also […]readmore
Shots: Novartis to get royalty-free worldwide, intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing […]readmore